

# Noevir Holdings Co., Ltd. Results for the First Half of Fiscal 2021

(October 1, 2020 - March 31, 2021)

May 14, 2021 Noevir Holdings Co., Ltd. Ikkou Yoshida, Director, Management Strategy and Public & Investor Relations



#### Noevir Holdings Co., Ltd.

Ticker:4928

Date of Establishment

**Paid-in Capital** 

**Consolidated Subsidiaries** 

Employees

Number of shareholders

**Outstanding Shares** 

Market Capitalization

Line of Business

March 22, 2011 (Noevir Co., Ltd. was founded in April 1964.) ¥7,319 million 13 subsidiaries (6 domestic / 7 international) 1,507 (Consolidated) (As of September 30, 2020) 19,025 (As of March 31, 2021) 34,156 thousand shares

¥164.293 billion (May 13, 2021 @ ¥4,810)





# 1. Results for the First Half of Fiscal 2021

- 2. The First Half of Fiscal 2021 Segment-Based Highlights
- 3. Medium-Term Management Plan
- 4. Forecasts and Initiatives for the Second Half of Fiscal 2021



# Sales and profits decreased due to the impact of COVID-19, but increased compared to planned company targets

|                         | 1st half of<br>fiscal 2021 | Year-on-year<br>change | Planned company<br>target (vs. forecast<br>target) |
|-------------------------|----------------------------|------------------------|--|
| Net sales               | 25,800 million yen         | (6.9%)                 | +1.4%  |
| Operating income        | 4,500 million yen          | (10.6%)                | +13.2%   |
| Operating income margin | 17.5%                      | (0.7pt)                | +1.8pt   |

Sales decreased mainly due to decreased sales of makeup lines, but sales of skincare lines increased


Operating income margin 17.5%



Net sales 25,860 million yen (down 6.9% YoY), operating income 4,529 million yen (down 10.6% YoY), ordinary income 4,626 million yen (down 9.9% YoY), net income attributable to owners of the parent 2,004 million yen (down 16.4% YoY).


|  | 1st half ended March 31,<br>2021 | 1st half ended March 31,<br>2020 | Year-on-ye      | ear change | Earnings fore   | ecast target |
|--|----------------------------------|----------------------------------|-----------------|------------|-----------------|--------------|
|  | Millions of yen                  | Millions of yen                  | Millions of yen | %          | Millions of yen | %            |
| Net sales  | 25,860                           | 27,789                           | (1,928)         | (6.9)      | 25,500          | 1.4          |
| Cost of sales  | 9,311                            | 10,024                           | (712)           | (7.1)      |                 |              |
| Gross profit   | 16,548                           | 17,765                           | (1,216)         | (6.8)      |                 |              |
| SG&A   | 12,019                           | 12,696                           | (677)           | (5.3)      |                 |              |
| Operating income   | 4,529                            | 5,068                            | (538)           | (10.6)     | 4,000           | 13.2         |
| Non-operating income/expenses                              | 96                               | 66                               | 30              | 45.3       |                 |              |
| Ordinary income  | 4,626                            | 5,135                            | (508)           | (9.9)      | 4,100           | 12.8         |
| Extraordinary income/loss                                  | 1                                | △0                               | 2               |            |                 |              |
| Income before income taxes                                 | 4,627                            | 5,134                            | (506)           | (9.9)      |                 |              |
| Income taxes   | 2,623                            | 2,735                            | (112)           | (4.1)      |                 |              |
| Net income attributable to owners of the parent            | 2,004                            | 2,398                            | (394)           | (16.4)     | 1,900           | 5.5          |
| Cost ratio (%)   | 36.0                             | 36.1                             | (0.1pt)         | —          | —               | _            |
| Operating income margin (%)                                | 17.5                             | 18.2                             | (0.7pt)         | —          | 15.7            | _            |
| Ordinary income margin (%)                                 | 17.9                             | 18.5                             | (0.6pt)         |            | 16.1            | _            |
| Net income attributable to owners of the parent margin (%) | 7.7                              | 8.6                              | (0.9pt)         | _          | 7.5             | _            |
| SG&A ratio (%)   | 46.5                             | 45.7                             | 0.8pt           | _          | —               |              |

#### Monthly Net Sales in the Cosmetics Segment Year on Year VI NOEVIR HOLDINGS



#### The First Half of Fiscal 2021 Reasons for Change in Operating Income





Copyright © 2021 Noevir Holdings Co., Ltd All Rights Reserved.



# 1. Results for the First Half of Fiscal 2021

# 2. The First Half of Fiscal 2021 Segment-Based Highlights


# 3. Medium-Term Management Plan

4. Forecasts and Initiatives for the Second Half of Fiscal 2021



#### The First Half of Fiscal 2021 Segment-Based Highlights

|                        | 1st half ended<br>March 31, 2021 | 1st half ended<br>March 31, 2020 | Year-on-ye      | ar change |
|------------------------|----------------------------------|----------------------------------|-----------------|-----------|
|                        | Millions of yen                  | Millions of yen                  | Millions of yen | %         |
| Cosmetics              |                                  |                                  |                 |           |
| Net sales              | 19,655                           | 21,182                           | (1,527)         | (7.2)     |
| Segment income         | 5,123                            | 5,683                            | (560)           | (9.9)     |
| Pharmaceuticals &      |                                  |                                  |                 |           |
| Health Food            |                                  |                                  |                 |           |
| Net sales              | 5,359                            | 5,597                            | (238)           | (4.3)     |
| Segment income         | 691                              | 688                              | 2               | 0.4       |
| Other                  |                                  |                                  |                 |           |
| Net sales              | 845                              | 1,008                            | (162)           | (16.2)    |
| Segment income         | 87                               | 92                               | (4)             | (4.9)     |
| Consolidated net sales | 25,860                           | 27,789                           | (1,928)         | (6.9)     |



Composition of net sales in the first half of fiscal 2021

| Cosmetics                        | Sales and profits decreased year on year<br>Face-to-face channel cosmetics and self-selection cosmetics performed sluggishly                     |
|----------------------------------|--|
| Pharmaceuticals &<br>Health Food | Sales declined and profits increased year on year<br>Profits increased from efficient management of selling, general and administrative expenses |
| Other                            | Sales and profits decreased year on year<br>Sales in the apparel-related business and the aviation-related business were sluggish                |

Copyright © 2021 Noevir Holdings Co., Ltd All Rights Reserved.

#### **The First Half of Fiscal 2021 Cosmetics**



|                                   | 1st half ended<br>March 31, 2021     | 1st half ended<br>March 31, 2020   | Year-on-year o    | change          |                         |
|-----------------------------------|--------------------------------------|--|-------------------|-----------------|-------------------------|
|                                   | Millions of yen                      | Millions of yen  | Change            | %               | Cos                     |
| Net sales                         | 19,655                               | 21,182   | (1,527)           | (7.2)           | 76                      |
| Segment<br>income                 | 5,123                                | 5,683  | (560)             | (9.9)           | mill                    |
|                                   | -                                    |  |                   |                 | Composition of net sale |
| ce-to-face<br>channel<br>osmetics | COVID-19<br>➤ Skincare sale          | sed year on year<br>s in line with prev<br><i>KLE SERUM</i> , a r<br>sales | vious year        |                 |                         |
| -selection                        | ➤ Sales decrea                       | sed for <i>excel</i> bra   | nd lineup due to  | COVID-19        |                         |
| osmetics                          | ≻ Nameraka H                         | onpo skincare bra  | and sales in line | with previous y | ear                     |
|                                   | > NOV brand a                        | cne series perfor  | med well          |                 |                         |
| erseas and                        | ➤ Increased sa                       |  |                   |                 |                         |
| M business<br>sales               | <ul> <li>&gt; OEM perform</li> </ul> |  |                   |                 |                         |

## The First Half of Fiscal 2021 Pharmaceuticals & Health Food

|                   | 1st half ended<br>March 31, 2021 | 1st half ended March<br>31, 2020 | Year-on-year change |       |
|-------------------|----------------------------------|----------------------------------|---------------------|-------|
|                   | Millions of yen                  | Millions of yen                  | Millions of yen     | %     |
| Net sales         | 5,359                            | 5,597                            | (238)               | (4.3) |
| Segment<br>income | 691                              | 688                              | 2                   | 0.4   |

- Sales decreased due to sluggish sales of drinks despite solid sales of nutritional supplements
- Profits increased from efficient management of selling, general and administrative expenses

## The First Half of Fiscal 2021 Other

|                   | 1st half ended<br>March 31, 2021 | 1st half ended March<br>31, 2020 | Year-on-year change |        |  |
|-------------------|----------------------------------|----------------------------------|---------------------|--------|--|
|                   | Millions of yen                  | Millions of yen                  | Millions of yen     | %      |  |
| Net sales         | 845                              | 1,008                            | (162)               | (16.2) |  |
| Segment<br>income | 87                               | 92                               | (4)                 | (4.9)  |  |

Sales in the apparel-related business and aviation-related business were sluggish due to COVID-19






Composition of net sales in the first half of fiscal 2021





JUNAYUMI Premium

*Min Min Da Ha* functional drink brand lineup



Composition of net sales in the first half of fiscal 2021

## **The First Half of Fiscal 2021 Balance Sheets**



(Millions of yen)

|                                  | Previous year<br>(As of March 31, 2020) | As of March 31, 2021 | Change  |
|----------------------------------|---|----------------------|---------|
| Current assets                   | 48,885                                  | 47,136               | (1,748) |
| Cash and cash equivalents        | 27,574                                  | 26,994               | (579)   |
| Notes and accounts receivable    | 9,926                                   | 9,568                | (357)   |
| Non-current assets               | 29,402                                  | 29,589               | 187     |
| Property, plant and equipment    | 23,336                                  | 22,738               | (598)   |
| Buildings and structures, net    | 5,594                                   | 5,459                | (134)   |
| Equipment and vehicles, net      | 2,059                                   | 1,380                | (678)   |
| Intangible assets                | 461                                     | 419                  | (41)    |
| Investments and other assets     | 5,603                                   | 6,432                | 828     |
| Investment securities            | 1,534                                   | 2,186                | 652     |
| Total assets                     | 78,287                                  | 76,726               | (1,561) |
| Current liabilities              | 9,349                                   | 9,193                | (155)   |
| Long-term liabilities            | 20,326                                  | 20,002               | (323)   |
| Guarantee deposits received      | 13,129                                  | 12,650               | (478)   |
| Total liabilities                | 29,675                                  | 29,196               | (479)   |
| Shareholders' equity             | 47,760                                  | 45,979               | (1,781) |
| Common stock                     | 7,319                                   | 7,319                | -       |
| Retained earnings                | 40,442                                  | 38,661               | (1,781) |
| Total net assets                 | 48,612                                  | 47,530               | (1,081) |
| Total liabilities and net assets | 78,287                                  | 76,726               | (1,561) |
| Equity ratio                     | 61.8%                                   | 61.5%                | (0.3pt) |



# 1. Results for the First Half of Fiscal 2021

2. The First Half of Fiscal 2021 Segment-Based Highlights

# 3. Medium-Term Management Plan

4. Forecasts and Initiatives for the Second Half of Fiscal 2021



Having positioned net sales, operating income and return on equity (ROE) as key management indicators, the Noevir Group aims to maximize its corporate value and enhance profitability.

| Medium-term<br>Management Plan<br>Concept | Realizing steady corporate growth by securing sustainability in every Group business segment   |
|---|--|
|   |  |
|   | <ol> <li>Pursue innovation and continuous profit generation in the<br/>domestic market</li> </ol>  |
| Five Policies                             | 2. Enhance our brand value   |
|   | <ol> <li>Accelerate efforts to diversify human resources and our<br/>corporate structure</li> </ol>  |
|   | <ol> <li>Strengthen our competitiveness by stepping up the<br/>diversification of our R&amp;D, production and logistics systems</li> </ol> |
|   | <ol> <li>Promote a management approach that is responsive to<br/>changes in the business environment</li> </ol>                            |



# 1. Results for the First Half of Fiscal 2021

2. The First Half of Fiscal 2021 Segment-Based Highlights

# 3. Medium-Term Management Plan

## 4. Forecasts and Initiatives for the Second Half of Fiscal 2021


## **Fiscal 2021 Forecasts**



|                                  | Net Sales       | Operating<br>Income | Ordinary<br>Income | Net Income<br>Attributable<br>to Owners of Parent |
|----------------------------------|-----------------|---------------------|--------------------|---|
|                                  | Millions of yen | Millions of yen     | Millions of yen    | Millions of yen                                   |
| 1st Half Results                 | 25,860          | 4,529               | 4,626              | 2,004   |
| 2nd Half Forecasts               | 26,639          | 4,470               | 4,573              | 4,295   |
| Full Year Forecasts (A)          | 52,500          | 9,000               | 9,200              | 6,300   |
|                                  |                 |                     |                    |   |
| Fiscal 2020 Results (B)          | 51,841          | 8,060               | 8,242              | 5,618   |
| Difference (A-B)                 | 658             | 939                 | 957                | 681   |
| Change                           | 1.3%            | 11.7%               | 11.6%              | 12.1%   |
|                                  |                 |                     |                    |   |
| 2nd Half Forecast (C)            | 26,639          | 4,470               | 4,573              | 4,295   |
| Fiscal 2020 2nd Half Results (D) | 24,052          | 2,992               | 3,107              | 3,219   |
| Difference (C-D)                 | 2,587           | 1,478               | 1,466              | 1,076   |
| Change                           | 10.8%           | 49.4%               | 47.2%              | 33.4%   |

### Fiscal 2021 Reasons for Change in Operating Income Forecast





(Forecast)

Forecast increase in operating income 940 million yen

Copyright © 2021 Noevir Holdings Co., Ltd All Rights Reserved.





### Strive for improved profitability as a core business

| Face-to-face<br>channel<br>cosmetics | Expand customer contact points in e-commerce and online based on face-to-face sales |
|--------------------------------------|---|
|                                      |   |
| Self-selection                       | Present products timely with an understanding                                       |

cosmetics

Present products timely with an understanding of customers' needs

Cosmetics



Face-to-face channel cosmetics

*Noevir* Focus on based on face-to face sales

#### Sales representatives conduct NOEVIR Beauty Studios salons

> Improve service quality, focus on sales

> Roll out to about 2,000 stores nationwide



#### Directly-managed NOEVIR Style and NOEVIR SALON DE SPECIALE stores

- Strengthen Customer Attraction and Profitability
- > Roll out 10 stores, mainly in major cities



**Cosmetics** 



Face-to-face channel cosmetics

Noevir

Promote use of e-commerce and online sales

## Improve convenience for sales representatives and customers

- For sales representatives Promote use of dedicated online ordering system NOEVIR Support
- For customers Release the EC NOEVIR official shopping application



NOEVIR official shopping application

## Strengthening online beauty education and counseling services

For sales representatives Beauty education including makeup training and new product presentations

#### For customers Counseling services ma

Counseling services matched to individual skincare concerns and the seasons



Online beauty training for sales representatives





Face-to-face channel cosmetics

#### *Noevir* Sell and focus on sales expansion of new products

# NOEVIR

LIPOSOME serum embodies the blessings of nature, advanced using cutting-edge biotech research

> *Noevir BIOSIGN INNER TREATMENT LIPOSOME* 19,800 yen (tax exclusive) On sale May, 2021







# Self-selection cosmetics

### excel brand

Sell and focus on sales expansion of attractive new products





excel skinny rich shadow SR11 brick brown On sale starting March 2021



*excel* brand lineup image model In-store display



Official *excel* brand lineup Instagram account Live streaming of new product releases





# Self-selection cosmetics

### Nameraka Honpo skincare brand

Acquire a wide array of customers and further expand earnings



\* Suppresses generation of melanin, prevents blemishes and freckles





# Self-selection cosmetics

## NOV brand Focus on Expanding Sales of Mainstay Series

# NOV



NOV III skincare line (Skincare for sensitive and dry skin)






NOV L&W skincare line (Highly moisturizing aging care for sensitive skin)





NOV AC ACTIVE skincare line (Proactive skincare for adult acne) Sales relaunched starting May 2021

## **Pharmaceuticals & Health Food**



> Strengthen orders for private brands, OEM

Major initiatives for

the second half fiscal 2021

| Pharmaceuticals | Aim to increase earnings by capturing new<br>customers through launch of special products and<br>new products, etc. |                     |
|-----------------|---|---------------------|
| Health Food     | Relaunched sales of <i>Min Min Da Ha</i> functional drink<br>brand lineup   |                     |
|                 | Deploy promotions using internet and social media   | ADCOURCES ADCOURCES |
|                 | 野<br>野<br>の<br>の<br>の<br>の<br>の<br>の<br>の<br>の  |                     |

Copyright © 2021 Noevir Holdings Co., Ltd All Rights Reserved.

Min Min Da Ha functional drink brand lineup Sales relaunched starting April 2021

DEVIR HOLDINGS



## > Improve Profitability

Other

### Apparel business


#### Launch new products

## NOEVIR





### Increased dividends for nine consecutive periods ¥200 ¥205 ¥205



# Continue stable shareholder return by maximizing corporate value and enhancing profitability

\* Dividend payout ratio for Fiscal 2011 was calculated from the sum of net income attributable to owners of the parent of Noevir Co, Ltd. for Q2 Fiscal 2011 and Noevir Holdings Co., Ltd. for Fiscal 2011.



[Inquiries] Noevir Holdings Co., Ltd. Public & Investor Relations Tel: +81-03-5568-0305 Fax: +81-03-5568-0441 E-mail: ir@noevirholdings.co.jp WEB: https://www.noevirholdings.co.jp/english/index.htm

These materials contain information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.